Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
Dusetzina SB, Sarpatwari A, Carrier MA, Hansen RA, Keating NL, Huskamp HA.
JAMA Intern Med. 2021 Oct 18. PMID: 34661600
Assistant Professor
Ameet Sarpatwari
Assistant Professor in the Department of Health Policy and Management
Health Policy and Management
Other Positions
Assistant Professor of Medicine
Medicine
Brigham and Women's Hospital
Links
Bibliography
The implications of Industry-Funded Disease Awareness Campaigns in the Rare Disease Setting.
Gill J, Sarpatwari A, Prasad V.
Mayo Clin Proc. 2021 09. 96(9):2305-2308. PMID: 34481596
Regulatory authority and clinical acceptability: Physicians' responses to regulatory drug safety warnings.
Bhasale AL, Sarpatwari A, Lipworth W, Møllebaek M, McEwin EJ, Gautam N, Santiago Ortiz A, Mintzes BJ.
Br J Clin Pharmacol. 2021 Aug 01. PMID: 34337777
Barriers To US Biosimilar Market Growth: Lessons From Biosimilar Patent Litigation.
Van de Wiele VL, Kesselheim AS, Sarpatwari A.
Health Aff (Millwood). 2021 08. 40(8):1198-1205. PMID: 34339242
Cost to Medicare of Delayed Adalimumab Biosimilar Availability.
Lee CC, Najafzadeh M, Kesselheim AS, Sarpatwari A.
Clin Pharmacol Ther. 2021 10. 110(4):1050-1056. PMID: 34145566
Frequency of First Generic Drug Approvals With "Skinny Labels" in the United States.
Walsh BS, Sarpatwari A, Rome BN, Kesselheim AS.
JAMA Intern Med. 2021 Jul 01. 181(7):995-997. PMID: 33779681
Civil commitment for opioid misuse: do short-term benefits outweigh long-term harms?
Messinger JC, Ikeda DJ, Sarpatwari A.
J Med Ethics. 2021 May 27. PMID: 34045279
Diabetes Drugs: List Price Increases Were Not Always Reflected In Net Price; Impact Of Brand Competition Unclear.
Sarpatwari A, Tessema FA, Zakarian M, Najafzadeh MN, Kesselheim AS.
Health Aff (Millwood). 2021 05. 40(5):772-778. PMID: 33939506
A Multi-modal Approach to Evaluate the Impact of Risk Evaluation and Mitigation Strategy (REMS) Programs.
Sarpatwari A, Mitra-Majumdar M, Bykov K, Avorn J, Woloshin S, Toyserkani GA, LaCivita C, Manzo C, Zhou EH, Pinnow E, Dal Pan GJ, Gagne JJ, Huybrechts KF, Feldman WB, Chin K, Kesselheim AS.
Drug Saf. 2021 Jul. 44(7):743-751. PMID: 33904111
Identifying potential prescription drug product hopping.
Gowda V, Beall RF, Kesselheim AS, Sarpatwari A.
Nat Biotechnol. 2021 04. 39(4):414-417. PMID: 33846649